Genmab Says Phase 3 EPCORE FL-1 Clinical Trial Met Dual Primary Endpoints In Patients With R/R FL

RefinitivMoins d'1 minute de lecture

Genmab A/S GMAB:

GENMAB ANNOUNCES PHASE 3 EPCORE® FL-1 CLINICAL TRIAL MET DUAL PRIMARY ENDPOINTS IN PATIENTS WITH RELAPSED/REFRACTORY (R/R) FOLLICULAR LYMPHOMA (FL)
GENMAB - FDA HAS ACCEPTED FOR PRIORITY REVIEW NEW SBLA FOR EPCORITAMAB PLUS R(2), WITH ACTION DATE OF NOVEMBER 30

© Copyright Thomson Reuters 2025. Click For Restrictions - https://agency.reuters.com/en/copyright.html

Connectez-vous ou créez un compte gratuit à vie pour lire ces nouvelles